Murat Terzi
A5009021406- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Polyomavirus and related diseases
- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Systemic Sclerosis and Related Diseases
- Systemic Lupus Erythematosus Research
- Immunotherapy and Immune Responses
- Acute Lymphoblastic Leukemia research
- Sphingolipid Metabolism and Signaling
- Health Systems, Economic Evaluations, Quality of Life
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- Neurological disorders and treatments
- Voice and Speech Disorders
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Restless Legs Syndrome Research
- Mycobacterium research and diagnosis
- Parkinson's Disease Mechanisms and Treatments
- Migraine and Headache Studies
- Myasthenia Gravis and Thymoma
- Peripheral Nerve Disorders
- Dysphagia Assessment and Management
- Dermatological and Skeletal Disorders
- Genomic variations and chromosomal abnormalities
Ondokuz Mayıs University
2016-2025
Biogen (Switzerland)
2024
Karolinska Institutet
2020-2024
Griffith University
2023
The University of Melbourne
2016-2023
QIMR Berghofer Medical Research Institute
2023
Barwon Health
2023
The University of Queensland
2023
University of Newcastle Australia
2023
University of Tasmania
2023
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory that typically affects the optic nerves and spinal cord. At least two thirds of cases are associated with aquaporin-4 antibodies (AQP4-IgG) complement-mediated damage to central nervous system. In previous small, open-label study involving patients AQP4-IgG–positive disease, eculizumab, terminal complement inhibitor, was shown reduce frequency relapse.
<h3>Importance</h3> Within 2 decades of onset, 80% untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase irreversible disability accrual termed secondary progressive MS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied never using validated definition. <h3>Objective</h3> To determine the use, type of, timing DMTs risk MS diagnosed <h3>Design, Setting, Participants</h3> Cohort study prospective data from...
Prevention of irreversible disability is currently the most important goal disease modifying therapy for multiple sclerosis. The outcomes used in clinical trials rely on progression Expanded Disability Status Scale score confirmed over 3 or 6 months. However, sensitivity and stability this metric has not been extensively evaluated. Using global MSBase cohort study, we evaluated 48 criteria progression, testing three definitions baseline disability, two magnitude, long-term irreversibility...
Objective In patients suffering multiple sclerosis activity despite treatment with interferon β or glatiramer acetate, clinicians often switch therapy to either natalizumab fingolimod. However, no studies have directly compared the outcomes of switching these agents. Methods Using MSBase, a large international, observational, prospectively acquired cohort study, we identified relapsing–remitting experiencing relapses disability progression within 6 months immediately preceding...
Background: Demyelinating lesions over 20 mm in size, referred to as tumefactive demyelinating lesions, can be misdiagnosed being either a tumor or an abscess. Although some radiological characteristics help make differential diagnosis easier, cerebral biopsy may still necessary. Objective: Our objective was assess the clinical of with without multiple sclerosis (MS), and present follow-up data for 54 patients lesions. Methods: Demographic, clinical, laboratory were gathered treatment...
Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response varies greatly among patients. Comprehensive predictive models individual are lacking. Our aims were: (i) to develop algorithms using demographic, clinical and paraclinical predictors patients with (ii) evaluate accuracy, internal external validity these algorithms. This study evaluated 27 seven disease-modifying therapies MSBase, a large global cohort study....
After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the relative effectiveness of different switch decisions often uncertain.To compare effect oral immunomodulator fingolimod with that all immunomodulators (interferons or glatiramer acetate) on rate, disability, and treatment persistence in patients active MS.Matched retrospective analysis data collected prospectively from MSBase, international,...
Oral immunotherapies have become a standard treatment in relapsing-remitting multiple sclerosis. Direct comparison of their effect on relapse and disability is needed.We identified all patients with sclerosis treated teriflunomide, dimethyl fumarate or fingolimod, minimum 3-month persistence follow-up the global MSBase cohort study. Patients were matched using propensity scores. Three pairwise analyses compared annualised rates hazards accumulation, improvement discontinuation (analysed...
Radiologically isolated syndrome (RIS) represents the earliest detectable preclinical phase of multiple sclerosis (MS) punctuated by incidental magnetic resonance imaging (MRI) white matter anomalies within central nervous system.
Importance Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells, reduces the frequency of relapses by 46% and disability worsening 40% compared with interferon beta 1a in relapsing-remitting multiple sclerosis (MS). Rituximab, chimeric anti-CD20 agent, is often prescribed as an off-label alternative to ocrelizumab. Objective To evaluate whether effectiveness rituximab noninferior ocrelizumab MS. Design, Setting, Participants This was observational cohort study...
Patients with pediatric-onset multiple sclerosis (POMS) typically experience higher levels of inflammation more frequent relapses, and though patients POMS usually recover from relapses better than adults, reach irreversible disability at a younger age adult-onset patients. There have been few randomized, placebo-controlled clinical trials (MS) disease-modifying therapies (DMTs) in POMS, most available data are based on observational studies off-label use DMTs approved for adults. We...
<h3>Background</h3> Age at onset (AAO) in multiple sclerosis (MS) is an important marker of disease severity and may have prognostic significance. Understanding what factors can influence AAO shed light on the aetiology this complex disease, applications diagnostic process. <h3>Methods</h3> The study cohort 22 162 eligible patients from 21 countries was extracted MSBase registry. Only with MS aged ≥16 years were included. To reduce heterogeneity, only centres largely European descent...
<h3>Objective</h3> To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS), we modeled outcomes 14,717 patients. <h3>Methods</h3> We studied patients from MSBase followed for ≥1 year, with ≥3 visits, visit per and exposed to MS therapy, a subset of ≥15-year follow-up. Marginal structural models were used compare cumulative hazards 12-month confirmed increase decrease disability, Expanded Disability Status Scale (EDSS) step 6,...
Background: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested. Objective: aim of this study was determine the demographic, clinical and paraclinical features that influence sclerosis. Methods: Patients with adult-onset relapsing–remitting at least four recorded disability scores were selected MSBase, a global observational cohort. objectively defined evaluated time points per patient using multivariable marginal Cox...
To investigate pregnancy-related disease activity in a contemporary multiple sclerosis (MS) cohort.Using data from the MSBase Registry, we included pregnancies conceived after 31 Dec 2010 women with relapsing-remitting MS or clinically isolated syndrome. Predictors of intrapartum relapse, and postpartum relapse disability progression were determined by clustered logistic regression Cox analyses.We 1998 1619 MS. Preconception annualized rate (ARR) was 0.29 (95% CI 0.27-0.32), fell to 0.19...
<h3>Background and Objectives</h3> To evaluate the rate of return disease activity after cessation multiple sclerosis (MS) disease-modifying therapy. <h3>Methods</h3> This was a retrospective cohort study from 2 large observational MS registries: MSBase OFSEP. Patients with relapsing-remitting who had ceased therapy were followed up for subsequent 12 months included in analysis. The primary outcome annualized relapse discontinuation stratified by patients did, did not, commence secondary...
Nutrition modulation can reduce multiple sclerosis (MS) related symptoms and fatigue severity. Mediterranean diet may be beneficial regarding anti-inflammatory components. However, previous studies are limited. This study aims to investigate the relationship between adherence MS-related severity.One hundred two adult MS patients were enrolled in this cross-sectional study. Dietary was assessed using assessment tool (MEDAS). determined symptom checklist (MS-RS), severity scale (FSS) applied....
Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS).
Patients with the 'aggressive' form of multiple sclerosis accrue disability at an accelerated rate, typically reaching Expanded Disability Status Score (EDSS) ≥ 6 within 10 years symptom onset. Several clinicodemographic factors have been associated aggressive sclerosis, but less research has focused on clinical markers that are present in first year disease. The development early predictive models is essential to optimize treatment this subtype. We evaluated whether patients who will...